Bloodwork Monitoring Guide for Peptide Research — VialBase Guides
Which blood tests to run before, during, and after peptide protocols — covering the top 10 most-used compounds.
Disclaimer: This guide is for informational and educational purposes only. It does not constitute medical advice. Consult a licensed physician before beginning any peptide protocol or interpreting bloodwork results.
Bloodwork is the objective record of what a compound is doing inside the body. Without a baseline, there is nothing to compare against. Without follow-up panels, there is no way to know whether markers have shifted. This guide covers what to test, when to test it, and what to watch for across the most widely researched peptides.
Why Bloodwork Matters
Three reasons to run blood panels around any peptide protocol:
- Baseline — Establishes your individual normal. Reference ranges are population averages; your personal values may sit at the high or low end and still be healthy for you. A pre-protocol draw captures that.
- Tracking — Catches shifts in real time. Some compounds affect IGF-1, glucose regulation, or thyroid function. Catching a 30% rise in fasting insulin mid-cycle lets you adjust before it becomes a problem.
- Recovery confirmation — Post-protocol labs confirm that markers have returned to baseline. This is especially important for GH-axis peptides and anything that modulates cortisol or insulin sensitivity.
Universal Baseline Panel
Run this panel for any peptide protocol, regardless of compound. Draw fasted (10–12 hours, water only).
| Test | What It Measures | Why It Matters |
|---|---|---|
| CMP (Comprehensive Metabolic Panel) | Glucose, electrolytes, kidney function, liver enzymes | Broad organ health snapshot; catches liver or kidney stress early |
| CBC (Complete Blood Count) | Red cells, white cells, platelets, hemoglobin | Flags infections, anemia, or immune shifts |
| Lipid Panel | Total cholesterol, LDL, HDL, triglycerides | GH-axis peptides can shift lipid profiles |
| Fasting Insulin | Circulating insulin level | Sensitive marker for insulin resistance; shifts before glucose does |
| Fasting Glucose + HbA1c | Immediate and 3-month average glucose | GLP-1 compounds and GH secretagogues both affect glucose metabolism |
| IGF-1 | Insulin-like Growth Factor 1 | Primary downstream marker for GH secretagogue activity |
| Thyroid Panel (TSH, Free T3, Free T4) | Thyroid output and feedback | Epithalon and some peptides may influence thyroid axis |
| CRP + ESR | Systemic inflammation | Baseline for any anti-inflammatory claims; catches unexpected immune activation |
Compound-Specific Monitoring
BPC-157 — Risk: Low
BPC-157 has a favorable preclinical safety profile with no reported significant lab abnormalities at research doses.
| Timepoint | Tests to Run |
|---|---|
| Baseline | CMP, CBC |
| Mid-cycle | Optional — CMP if GI symptoms present |
| Post (4–6 weeks) | CMP, CBC |
Key markers: ALT, AST (liver); BUN, creatinine (kidney). Expect no significant movement.
CJC-1295 + Ipamorelin — Risk: Moderate (GH axis)
This combination stimulates GH release, which downstream elevates IGF-1. Sustained IGF-1 elevation above range is the primary monitoring concern.
| Timepoint | Tests to Run |
|---|---|
| Baseline | Full panel (CMP, CBC, Lipid, IGF-1, Fasting Glucose, Fasting Insulin) |
| Mid-cycle (4–6 weeks) | IGF-1, Fasting Glucose, Fasting Insulin |
| Post (4–6 weeks) | IGF-1, Fasting Glucose, Lipid |
Key markers: IGF-1 (target: within age-appropriate range), fasting insulin (watch for creeping insulin resistance), fasting glucose.
Semaglutide / Tirzepatide — Risk: Moderate (metabolic)
GLP-1 and dual GLP-1/GIP agonists directly affect glucose metabolism and have documented effects on lipids and pancreatic markers.
| Timepoint | Tests to Run |
|---|---|
| Baseline | CMP, CBC, Lipid, Fasting Glucose, HbA1c, Fasting Insulin, Amylase/Lipase |
| Mid-cycle (8 weeks) | Fasting Glucose, HbA1c, Lipid, Amylase/Lipase |
| Post (6–8 weeks) | Full metabolic panel |
Key markers: Fasting glucose and HbA1c (expect improvement in insulin-resistant subjects), LDL (often improves), amylase/lipase (rule out pancreatic stress).
TB-500 (Thymosin Beta-4 fragment) — Risk: Low-Moderate
Primarily studied for tissue repair. Low systemic risk but warrants monitoring given the limited human data.
| Timepoint | Tests to Run |
|---|---|
| Baseline | CMP, CBC, CRP |
| Mid-cycle | CBC, CRP |
| Post (4–6 weeks) | CMP, CBC |
Key markers: CBC (particularly WBC for immune shifts), CRP (anti-inflammatory signal vs. unexpected elevation).
Epithalon — Risk: Low
Peptide associated with telomere and pineal axis research. Low acute risk profile.
| Timepoint | Tests to Run |
|---|---|
| Baseline | CMP, CBC, Thyroid (TSH, Free T3, Free T4) |
| Post (4–6 weeks) | Thyroid panel, CMP |
Key markers: Thyroid panel — some research suggests pineal-axis interactions. Watch for TSH shifts.
GHK-Cu — Risk: Low (watch copper)
Copper peptide used in regenerative and anti-aging research. The copper component warrants attention at high doses or prolonged use.
| Timepoint | Tests to Run |
|---|---|
| Baseline | CMP, CBC, Serum Copper, Ceruloplasmin |
| Post (4–6 weeks) | Serum Copper, CBC |
Key markers: Serum copper and ceruloplasmin. Excess copper can suppress zinc; consider adding serum zinc to the panel for extended protocols.
GHRP-2 / GHRP-6 — Risk: Moderate (cortisol, prolactin)
Older GH secretagogues with broader receptor activity than ipamorelin. Both stimulate cortisol and prolactin alongside GH.
| Timepoint | Tests to Run |
|---|---|
| Baseline | CMP, CBC, IGF-1, Fasting Glucose, Cortisol (AM), Prolactin |
| Mid-cycle (4 weeks) | IGF-1, Cortisol (AM), Prolactin, Fasting Glucose |
| Post (4–6 weeks) | Full GH-axis panel |
Key markers: AM cortisol (elevated chronically = HPA stress), prolactin (watch for supraphysiologic levels), IGF-1.
Semax / Selank — Risk: Low
Nootropic peptides targeting cognitive and anxiolytic pathways. Minimal systemic metabolic impact expected.
| Timepoint | Tests to Run |
|---|---|
| Baseline | CMP, CBC |
| Post (4–6 weeks) | CMP if extended use |
Key markers: Routine CMP markers. No specific high-risk targets identified in preclinical literature.
PT-141 (Bremelanotide) — Risk: Low-Moderate (blood pressure)
Melanocortin receptor agonist used in sexual health research. Known transient blood pressure elevation is the primary concern.
| Timepoint | Tests to Run |
|---|---|
| Baseline | CMP, CBC, Blood Pressure (BP) reading |
| Per-use monitoring | BP check 30–60 min post-administration |
| Post (4–6 weeks) | CMP if frequent use |
Key markers: Blood pressure. Transient elevations of 6–13 mmHg systolic have been documented in clinical trials. Not recommended for subjects with uncontrolled hypertension.
Reference Ranges
These are general adult reference ranges. Individual lab ranges may vary slightly.
| Marker | Standard Range | Notes |
|---|---|---|
| IGF-1 | Age-dependent; ~115–307 ng/mL (ages 25–39) | Always compare to age-matched range |
| Fasting Glucose | 70–99 mg/dL | ≥100 = impaired fasting glucose |
| HbA1c | < 5.7% | 5.7–6.4% = prediabetes range |
| Fasting Insulin | 2–20 µIU/mL | Optimal < 10; higher = insulin resistance signal |
| TSH | 0.4–4.0 mIU/L | Many practitioners prefer 1–2.5 as functional optimal |
| Free T3 | 2.3–4.1 pg/mL | Active thyroid hormone |
| Free T4 | 0.8–1.8 ng/dL | Prohormone; converted to T3 |
| ALT | 7–56 U/L | Liver-specific enzyme |
| AST | 10–40 U/L | Liver + muscle; elevated in both |
| CRP (hs-CRP) | < 1.0 mg/L (low risk) | > 3.0 = high cardiovascular risk signal |
| Cortisol (AM) | 6–23 µg/dL | Draw 8–9 AM fasted |
Practical Tips
- Fast properly. 10–12 hours before the draw, water only. This applies to glucose, insulin, and lipid panels. Non-fasted values are not comparable to fasted baselines.
- Consistent timing. Draw follow-up panels at the same time of day as your baseline. Cortisol and some hormones have diurnal variation.
- Note your protocol. Document what compound, dose, and schedule you were on when each panel was drawn. Labs without context are difficult to interpret later.
- Track trends, not snapshots. A single high value is less informative than a value that has risen 40% from your own baseline, even if it remains within the population reference range.
- Use a spreadsheet. Log each test date and result. Simple trend-spotting over two or three panels is more useful than any single draw.
When to Stop — Red Flags
Stop the protocol and consult a physician if any of the following appear:
- IGF-1 > 400 ng/mL on GH-axis compounds — sustained supraphysiologic levels carry acromegaly-adjacent risks
- Fasting glucose > 126 mg/dL on two consecutive draws — diagnostic threshold for diabetes
- ALT or AST > 3× upper limit of normal — indicates significant hepatocellular stress
- AM cortisol < 5 µg/dL — suggests adrenal suppression requiring evaluation
- Prolactin > 30 ng/mL (men) or > 50 ng/mL (non-pregnant women) — warrants investigation for pituitary involvement
- Unexplained WBC elevation — could indicate immune activation or infection
- Persistent blood pressure > 140/90 mmHg on PT-141 — do not continue until evaluated
Bloodwork does not make a protocol safe. It makes it legible. The goal is to catch problems early, confirm recovery, and build a personal reference record over time.